Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.

PubWeight™: 1.12‹?› | Rank: Top 10%

🔗 View Article (PMID 12152004)

Published in Clin Pharmacol Ther on July 01, 2002

Authors

J I Schwartz1, K Vandormael, M P Malice, R N Kalyani, K C Lasseter, G B Holmes, B J Gertz, K M Gottesdiener, M Laurenzi, K-J Redfern, K Brune

Author Affiliations

1: Merck Research Laboratories, Rahway, NJ 07065, USA. jules_schwartz@meck.com

Articles citing this

Estimated GFR reporting is associated with decreased nonsteroidal anti-inflammatory drug prescribing and increased renal function. Kidney Int (2013) 2.11

Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology (2009) 1.19

Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer (2004) 1.10

Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol (2007) 1.03

Nonsteroidal Anti-Inflammatory Drugs and the Kidney. Pharmaceuticals (Basel) (2010) 0.89

Prostaglandin E2 EP3 receptor regulates cyclooxygenase-2 expression in the kidney. Am J Physiol Renal Physiol (2012) 0.84

Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain. Biochem J (2005) 0.84

Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn Schmiedebergs Arch Pharmacol (2006) 0.83

NSAIDs: the emperor's new dogma? Gut (2003) 0.82

Water displacement leg volumetry in clinical studies--a discussion of error sources. BMC Med Res Methodol (2010) 0.82

Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) (2016) 0.81

[From willow bark to the coxibs. Development of antiphlogistic analgesics]. Schmerz (2007) 0.81

Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and Mice. PLoS One (2015) 0.77

Eicosanoids and tumor necrosis factor-alpha in the kidney. Prostaglandins Other Lipid Mediat (2011) 0.76

Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte Blood Press (2008) 0.76

Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib. Br J Clin Pharmacol (2008) 0.75

Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue. Cureus (2017) 0.75

The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugs. Clin Rheumatol (2005) 0.75

Articles by these authors

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38

Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med (2000) 2.82

Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax (2000) 2.74

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation (2001) 2.55

Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther (2007) 2.53

Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology (2001) 2.29

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med (1999) 2.18

Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther (1999) 2.10

Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98

Assessment of phagocytic and antimicrobial activity of human granulocytes. Infect Immun (1974) 1.96

Quantitative detection of Borrelia burgdorferi by real-time PCR. J Clin Microbiol (1999) 1.93

The venous graft as an effector of early angiogenesis in a fibrin matrix. Microvasc Res (2007) 1.93

Women encounter ADRs more often than do men. Eur J Clin Pharmacol (2008) 1.83

Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol (2000) 1.70

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer (2001) 1.65

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract (2009) 1.61

Gastrointestinal ulcerations induced by anti-inflammatory drugs in rats. Physicochemical and biochemical factors involved. Arch Toxicol (1990) 1.59

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum (2001) 1.58

Piperacillin kinetics. Clin Pharmacol Ther (1979) 1.57

Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. J Clin Endocrinol Metab (1994) 1.55

Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf (2000) 1.51

Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract (2008) 1.50

First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg (1998) 1.48

Pharmacological control of prostaglandin and thromboxane release from macrophages. Nature (1978) 1.44

Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med (2004) 1.42

Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol (2000) 1.42

Failure of the metal-backed patellar component after total knee replacement. J Bone Joint Surg Am (1988) 1.40

Peroxidaseless chicken leukocytes: isolation and characterization of antibacterial granules. J Infect Dis (1973) 1.39

Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther (2008) 1.38

Inhibition of anti-inflammatory drugs of prostaglandin production in cultured macrophages. Naunyn Schmiedebergs Arch Pharmacol (1981) 1.36

Improved separation of chromosome-sized DNA from Trypanosoma brucei, stock 427-60. Nucleic Acids Res (1989) 1.35

Molecular cloning of complementary DNAs encoding the heavy chain of the human 4F2 cell-surface antigen: a type II membrane glycoprotein involved in normal and neoplastic cell growth. Proc Natl Acad Sci U S A (1987) 1.35

Leukocytes and prostaglandins in acute inflammation. Experientia (1974) 1.35

Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res (1997) 1.35

Drug therapy. Sodium nitroprusside. N Engl J Med (1975) 1.34

Pharmacokinetics of alendronate. Clin Pharmacokinet (1999) 1.31

Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett (1996) 1.30

Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Arch Intern Med (1998) 1.29

Elevated serum cyclophilin levels in patients with severe sepsis. J Clin Immunol (1997) 1.28

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab (1997) 1.25

Computerized surveillance of adverse drug reactions in hospital: implementation. Eur J Clin Pharmacol (1999) 1.24

Renal effects of COX-2-selective inhibitors. Am J Nephrol (2001) 1.24

Structure, expression and regulation of the murine 4F2 heavy chain. Nucleic Acids Res (1989) 1.23

Central effect of the non-steroid anti-inflammatory agents, indomethacin, ibuprofen, and diclofenac, determined in C fibre-evoked activity in single neurones of the rat thalamus. Pain (1990) 1.23

Low glomerular filtration in the population: prevalence, associated disorders, and awareness. Kidney Int (2006) 1.22

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther (1999) 1.22

The effect of sulfonylurea drugs on rabbit myocardial contractility, canine purkinje fiber automaticity, and adenyl cyclase activity from rabbit and human hearts. J Clin Invest (1972) 1.21

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) (2002) 1.20

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol (2001) 1.19

Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol (1999) 1.18

Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol (2000) 1.17

The effects of wearing high heeled shoes on pedal pressure in women. Foot Ankle (1992) 1.17

Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology (1989) 1.17

Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. J Cardiovasc Pharmacol (1984) 1.17

Possible role of oxygen free radicals in ethanol-induced gastric mucosal damage in rats. Dig Dis Sci (1988) 1.17

Profile of etodolac: pharmacokinetic evaluation in special populations. Clin Rheumatol (1989) 1.16

Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1992) 1.15

Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther (1995) 1.14

Biodistribution of mild analgesics. Br J Clin Pharmacol (1980) 1.12

The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab (1993) 1.11

Acidic nonsteroid anti-inflammatory drugs accumulating in inflamed tissue. Experientia (1975) 1.11

Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res (1996) 1.11

Microbicidal activity of peroxidaseless chicken heterophile leukocytes. Infect Immun (1972) 1.10

Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol (1999) 1.10

Correlation between antimicrobial activity and peroxidase content of leukocytes. Nature (1973) 1.10

Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth (1993) 1.10

Stimulation of Na+ and K+ dependent adenosine triphosphatase by ouabain. Arch Biochem Biophys (1966) 1.09

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone (1995) 1.09

Prostaglandin E(2) upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem Biophys Res Commun (2000) 1.08

Prostaglandin release from macrophages: an assay system for anti-inflammatory drugs in vitro. Agents Actions (1977) 1.08

A detailed mutational analysis of the VSG gene expression site promoter. Mol Biochem Parasitol (1996) 1.07

Effect of anti-inflammatory and analgesic pyrazoles on arachidonic acid metabolism in isolated heart and gastric mucosa preparations. Agents Actions Suppl (1986) 1.07

Effects of pentazocine and acetylsalicylic acid on pain-rating, pain-related evoked potentials and vigilance in relationship to pharmacokinetic parameters. Agents Actions (1990) 1.06

Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. Br J Clin Pharmacol (1994) 1.05

Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. A survey of their analgesic efficacy. Drugs (1991) 1.04

Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin Pharmacol Ther (1999) 1.04

Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. J Rheumatol (1999) 1.04

Potent and selective peptide agonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. Biochem Biophys Res Commun (2001) 1.03

Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol (1992) 1.02

Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol (2008) 1.02

Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol (2000) 1.02

Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. Clin Pharmacol Ther (1999) 1.01

Serum antibodies against chondrocyte cell surface proteins in osteoarthritis and rheumatoid arthritis. J Rheumatol (1988) 1.01

Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol (1997) 1.01

Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab (1990) 1.01

Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group. J Urol (1999) 1.01

Electrocardiogram in pericarditis. Am J Cardiol (1970) 1.00

Computerized survelliance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol (1998) 1.00

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther (2000) 1.00

Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E(2), and nonsteroidal anti-inflammatory drugs. Biochem Biophys Res Commun (2000) 0.99

Suppressed injury-induced rise in spinal prostaglandin E2 production and reduced early thermal hyperalgesia in iNOS-deficient mice. J Neurosci (2000) 0.99

Effects of pure enantiomers of flurbiprofen in comparison to racemic flurbiprofen on eicosanoid release from various rat organs ex vivo. Prostaglandins (1991) 0.99

Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. J Clin Invest (1989) 0.98

Elevated blood pressure and positive history of kidney stones: results from a population-based study. J Hypertens Suppl (1988) 0.98

Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol (2001) 0.98

The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin. Clin Pharmacol Ther (2000) 0.98